If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection. The medical community has long recognized the importance of balancing treatment benefits with potential risks, and this understanding has deepened with ongoing research. This page covers the latest FDA label updates, key symptoms to watch for, and what monitoring involves.
In the occupational sphere, this transition becomes particularly salient for individuals who may have been exposed to Tysabri through professional or caregiving roles, such as healthcare workers or family members administering treatment. The risk of PML in these contexts raises questions about workplace safety protocols and legal accountability. Consequently, the conversation naturally pivots from broad health literacy to the specific occupational exposure concern, highlighting the need for specialized legal guidance in cases where exposure leads to injury. This transition underscores the importance of bridging general awareness with practical, case-specific considerations.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a demyelinating disease that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can vary, but common symptoms include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is based on clinical evaluation, brain imaging (typically MRI showing characteristic white matter lesions), and laboratory detection of JCV DNA in cerebrospinal fluid (https://pubmed.ncbi.nlm.nih.gov/40922664/). A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 found that the condition can present with changing clinical and laboratory characteristics over time, depending on the underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/).
The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into the brain. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. As a result, latent JCV, which is present in many individuals without causing disease, can reactivate and infect oligodendrocytes in the brain, leading to PML. The FDA-approved labeling identifies three specific risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The boxed warning emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom suggestive of PML and withhold dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue in legal and settlement considerations. The FDA's boxed warning clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use, and that these factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to manage the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For affected patients, settlement-related considerations often involve the timeline between exposure to Tysabri and documented harm. PML can develop after varying durations of treatment, with risk increasing beyond two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML was observed after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The severe outcomes associated with PML, including death and permanent disability, underscore the importance of timely diagnosis and intervention. Patients who develop PML after Tysabri treatment may pursue legal claims alleging inadequate warnings or failure to monitor. The FDA's boxed warning and the TOUCH program represent regulatory efforts to mitigate risk, but individual cases may involve questions about whether healthcare providers and patients were fully informed of the risks. Settlement amounts in such cases can vary based on factors including the severity of the patient's injury, the duration of treatment, and the presence of known risk factors.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The FDA identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Yes, patients who develop PML after Tysabri treatment may pursue legal claims alleging inadequate warnings or failure to monitor. Settlement amounts vary based on injury severity, treatment duration, and risk factors.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.